Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: CD34+ cells are associated with rarer patterns of hippocampal sclerosis. A–D, I–J. A CD34+ nodular case. CD34 immunopositive/CD34+ stellate cells formed a nodule (solid arrowheads in (A‐B). Nestin immunolabeling showed a frequent extravascular stellate pattern in the area of the CD34+ nodule (solid arrowhead in C) whereas Vimentin immunolabeling showed no extravascular immunolabeling (D). E–H, K–L. A CD34+ scarce case. E. An isolated CD34+ extravascular stellate cell is observed (open arrowheads in E, F). Nestin immunolabeling showed a scant stellate extravascular pattern in the area of the CD34+ stellate cell (open arrowhead in G) whereas Vimentin immunolabeling showed no extravascular immunolabeling (H). Double immunolabelings showed the co‐expression in stellate cells of Nestin (brown) and CD34 (red) (I), and SOX2 (pink) and CD34 (brown) (J) in a CD34+ nodular case. Double immunolabelings showed the co‐expression in stellate cells of Nestin (brown) and CD34 (red) (K, higher magnification in insert), and of SOX2 (pink) and CD34 (brown) (L) in a CD34+ scarce case. M–P. Distribution of CD34 immunolabeling (CD34 negative in black, CD34+ scarce in orange and CD34+ nodular in green) for type 1 (M), type 2 (N), type 3 (O), the pattern noHS (P). Q–S. A CD34+ nodular case with BRAF V600E immunopositive neurons. Q. A moderate immunolabeling of scarce cells by P53 (solid arrowheads). The BRAF V600E immunolabeling is positive in neurons (solid arrowheads in r,s). T. A CD34+ scarce case with BRAF V600E+ neurons (open arrowhead). Scale bars: (A,E) 400 μm; (B–D,F–H) 100 μm; (I–L,T) 50μm; (Q,R) 200μm; (S) 20μm.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Immunolabeling, Isolation, Expressing

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: Classification of CD34+ hippocampal sclerosis according to BRAF V600E and INA status. A,C,E,G–I. A case of “BRAF V600E+ HS” with BRAF V600E positive neurons. B,D,F,J–L. A case of hippocampal MVNT. A,B. CD34 immunolabeling showed a nodular pattern of CD34 positive stellate cells (solid arrowheads). C,D. NeuN immunolabeling showed a neuronal loss that is predominant in CA4 (solid arrowheads) corresponding to HS ILAE type 3. E. Absence of INA positive abnormal neurons. F. Presence of numerous abnormal INA+ neurons (solid arrowheads). G–I. Absence of abnormal neurons according to NeuN, ELAVL2 and INA immunolabelings in the white matter of CA2 (open arrowheads) in a BRAF V600E+ HS. J–L. Presence of Neun Negative, ELAVL2 positive, INA positive abnormal neurons (solid arrowheads) in the white matter of CA2 in a MVNT. Scale bars: (A–F) 2.5 mm; (G–L) 200 μm. Abbreviations: INA = internexin alpha; MVNT = multinodular and vacuolating neuronal tumor.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Immunolabeling

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: Radiological features of BRAF V600E+ hippocampal sclerosis and hippocampal MVNT. A‐B. BRAF V600E+ hippocampal sclerosis. Coronal T2 sequence showing discrete atrophy, loss of digitation and T2 hyperintensity of the right hippocampus (vertical arrows). C–E. Hippocampal MVNT. Coronal T2 (C), FLAIR (D) and T1 (E) sequences show discrete atrophy of left internal temporal structures (vertical arrows), associated with extensive T2 and FLAIR hyperintensities involving the hippocampus, parahippocampal gyrus, fusiform gyrus and part of the inferior temporal gyrus (oblique arrows). A pseudocyst (arrowheads) is visible within the fusiform gyrus, hyperintense on T2 and hypointense on T1 and FLAIR images.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Sequencing

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: RT-qPCR experiments to explore the expression of AHNAK2 in 10 PTC tissues and 10 adjacent tissues

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Quantitative RT-PCR, Expressing

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Expression of different immunohistochemical markers in thyroid tumors. A1: PTC (H&E, × 200); A2: NIFTP (H&E, × 200); A3: FTC (H&E, × 200); A4: FA (H&E, × 200); A5: LT (H&E, × 200); A6: (H&E, × 200); B1: Diffuse positive staining of AHNAK2 in PTC cell membranes and cytoplasm (AHNAK2, × 200); B2: Focal cell membrane positivity of AHNAK2 in NIFTP cell membranes (AHNAK2, × 200); B3: Focal positive staining of AHNAK2 in FTC cell membranes (AHNAK2, × 200); B4: Negative staining of AHNAK2 in FA (AHNAK2, × 200); B5: Negative staining of AHNAK2 in lymphocytic thyroiditis (AHNAK2, × 200); B6: No expression of AHNAK2 in normal thyroid tissue (AHNAK2, × 200); C1: Diffuse cytoplasmic positivity of galectin-3 in PTC (galectin-3, × 200); C2: focal positivity of galectin-3 in NIFTP (galectin-3, × 200); C3: negative reaction of galectin-3 in FTC (galectin-3, × 200); C4: Negative staining of galectin-3 in FA, with staining of histocyte (galectin-3, × 200); C5: Negative reaction of galectin-3 in lymphocytic thyroiditis (galectin-3, × 200); C6: Negative staining of galectin-3 in normal thyroid tissue (galectin-3, × 200); D1: Diffuse cytoplasmic strong positivity of BRAF V600E in PTC (BRAF V600E, × 200); D2-6: Negative staining of BRAF V600E in NIFTP, FTC, FA, lymphocytic thyroiditis and normal thyroid tissue, with non-specific adsorption in the follicular lumen. (BRAF V600E, × 200); E1-4: Focal marginal staining of HBME-1 in PTC, NIFTP, FTC, FA (HBME-1, × 200); E5-6: No expression of HBME-1 in lymphocytic thyroiditis and normal thyroid tissue (HBME-1, × 200); F1-5: Diffuse membrane staining of CK19 in PTC, NIFTP, FTC, FA, and lymphocytic thyroiditis (CK19, × 200); F6: Diffuse staining of CK19 in surrounding normal thyroid tissue, with lower staining intensity than tumor tissue (CK19, × 200); G1-4: Diffuse nuclear staining of cyclin-D1 in PTC, NIFTP, FTC, and FA (cyclin-D1, × 200); G5: Focal nuclear staining of cyclin-D1 in lymphocytic thyroiditis (cyclin-D1, × 200); G6: Point-like nuclear staining of cyclin-D1 in surrounding thyroid tissue (cyclin-D1, × 200); H1: Mostly membrane positivity of TPO in PTC (TPO , × 200); H2-6: Diffuse membrane positivity of TPO in PTC (TPO , × 200); I1: Partial membrane positivity of CD56 in PTC (CD56 , × 200); I2: Negative reaction of CD56 in NIFTP (CD56 , × 200); I3: Focal membrane staining of CD56 in FTC (CD56 , × 200); I4-6: Diffuse membrane staining of CD56 in FA, lymphocytic thyroiditis, and normal thyroid tissue (CD56 , × 200)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Expressing, Immunohistochemical staining, Staining, Membrane, Negative Staining, Adsorption

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves of various immunohistochemical markers for distinguishing benign and malignant thyroid tumors (The areas under the curve (AUC) were as follows: AHNAK2=0.964; Galectin-3=0.935; BRAF=0.907; HBME-1=0.882; Cyclin-D1=0.776; CK19=0.752; CD56=0.053; TPO=0.004)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Immunohistochemical staining

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Positive distribution ranges of AHNAK2, galectin-3, and BRAF V600E in PTC. (The positive rate of AHNAK2, galectin-3, and BRAF V600E in PTC were 95%, 89.5%, and 82.4%, respectively. The diffuse positive rate were 59.1%, 68.6%, and 77.7%, respectively.)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques:

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Positive status of the combination of AHNAK2, Galectin-3, and BRAF V600E in PTC. (222 cases were positive for all three markers.)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques:

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Positivity rates/ number of cases of the combination of AHNAK2, galectin-3, and BRAF V600E in PTC. (The positive rate of all three markers was 75.00%.)

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques:

Journal: Diagnostic Pathology

Article Title: Diagnostic value of AHNAK2 immunohistochemical expression in papillary thyroid carcinoma: an immunohistochemical study

doi: 10.1186/s13000-025-01723-1

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves for the combined diagnosis of benign and malignant thyroid tumors using three immunohistochemical markers. (The areas under the curve (AUC) were as follows: AHNAK2 or galectin-3 or BRAF V600E=0.992; AHNAK2 or BRAF V600E=0.989; AHNAK2 or galectin-3=0.986; galectin-3 or BRAF V600E=0.969）

Article Snippet: AHNAK2 Galectin-3 BRAF V600E , 93.9 , 96.3 , 97.6 , 95.1 , 98.7 , 0.992(0.977–0.996) , < 0.001.

Techniques: Biomarker Discovery, Immunohistochemical staining